Actinium: Actinium. A trivalent radioactive element and the prototypical member of the actinide family. It has the atomic symbol Ac, atomic number 89, and atomic weight 227.0278. Its principal isotope is 227 and decays primarily by beta-emission.Thorium: Thorium. A radioactive element of the actinide series of metals. It has an atomic symbol Th, atomic number 90, and atomic weight 232.04. It is used as fuel in nuclear reactors to produce fissionable uranium isotopes. Because of its radioopacity, various thorium compounds are used to facilitate visualization in roentgenography.Executive Function: A set of cognitive functions that controls complex, goal-directed thought and behavior. Executive function involves multiple domains, such as CONCEPT FORMATION, goal management, cognitive flexibility, INHIBITION control, and WORKING MEMORY. Impaired executive function is seen in a range of disorders, e.g., SCHIZOPHRENIA; and ADHD.Ownership: The legal relation between an entity (individual, group, corporation, or-profit, secular, government) and an object. The object may be corporeal, such as equipment, or completely a creature of law, such as a patent; it may be movable, such as an animal, or immovable, such as a building.Pharmaceutical Preparations: Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.Drug Industry: That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.Periodicals as Topic: A publication issued at stated, more or less regular, intervals.Journal Impact Factor: A quantitative measure of the frequency on average with which articles in a journal have been cited in a given period of time.Neuropsychological Tests: Tests designed to assess neurological function associated with certain behaviors. They are used in diagnosing brain dysfunction or damage and central nervous system disorders or injury.Drug Approval: Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.Orphan Drug Production: Production of drugs or biologicals which are unlikely to be manufactured by private industry unless special incentives are provided by others.Rare Diseases: A large group of diseases which are characterized by a low prevalence in the population. They frequently are associated with problems in diagnosis and treatment.Pursuit, Smooth: Eye movements that are slow, continuous, and conjugate and occur when a fixed object is moved slowly.Biopharmaceutics: The study of the physical and chemical properties of a drug and its dosage form as related to the onset, duration, and intensity of its action.Legislation, Drug: Laws concerned with manufacturing, dispensing, and marketing of drugs.Immunotherapy: Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.Appointments and Schedules: The different methods of scheduling patient visits, appointment systems, individual or group appointments, waiting times, waiting lists for hospitals, walk-in clinics, etc.Cancer Vaccines: Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.Patient Care Team: Care of patients by a multidisciplinary team usually organized under the leadership of a physician; each member of the team has specific responsibilities and the whole team contributes to the care of the patient.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Sialic Acid Binding Ig-like Lectin 3: A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE.Alpha Particles: Positively charged particles composed of two protons and two NEUTRONS, i.e. equivalent to HELIUM nuclei, which are emitted during disintegration of heavy ISOTOPES. Alpha rays have very strong ionizing power, but weak penetrability.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).Antibody Specificity: The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Antibodies, Viral: Immunoglobulins produced in response to VIRAL ANTIGENS.Antibodies, Bacterial: Immunoglobulins produced in a response to BACTERIAL ANTIGENS.Posters as Topic: Single or multi-sheet notices made to attract attention to events, activities, causes, goods, or services. They are for display, usually in a public place and are chiefly pictorial.Congresses as Topic: Conferences, conventions or formal meetings usually attended by delegates representing a special field of interest.Erythrovirus: A genus of the family PARVOVIRIDAE, subfamily PARVOVIRINAE, and containing the type species PARVOVIRUS B19, HUMAN.Societies, Medical: Societies whose membership is limited to physicians.Hematology: A subspecialty of internal medicine concerned with morphology, physiology, and pathology of the blood and blood-forming tissues.Breech Presentation: A malpresentation of the FETUS at near term or during OBSTETRIC LABOR with the fetal cephalic pole in the fundus of the UTERUS. There are three types of breech: the complete breech with flexed hips and knees; the incomplete breech with one or both hips partially or fully extended; the frank breech with flexed hips and extended knees.Version, Fetal: The artificial alteration of the fetal position to facilitate birth.Societies, Scientific: Societies whose membership is limited to scientists.
(1/23) Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.

Preclinical evaluation of alpha particle-emitting 213Bi-labeled antibody constructs have demonstrated the specificity and potency of these agents in a variety of cancer systems. The transition of a 213Bi-radiolabeled antibody from a preclinical construct to a clinical drug represented a difficult task that involved development of reliable and validated methods to provide multiple MBq quantities of a pure, immunoreactive agent that met pharmaceutical standards to treat patients. METHODS: The methods used for the preparation of (213Bi)CHX-A-diethylenetriamine pentaacetic acid (DTPA)-HuM195, an alpha particle-emitting anti-CD33 antibody construct for therapy of myeloid leukemias, is used as a specific example. This article describes methods for reagent purification, drug labeling, radioprotection and chromatographic purification. Quality of the drug is evaluated using radiochemical incorporation and purity assays with instant thin-layer chromatography (ITLC) and high-performance liquid chromatography (HPLC), determination of cell-based antibody total immunereactivity, small animal safety, pyrogen level, sterility and radionuclidic purity. RESULTS: Sixty-seven doses were prepared. Individual doses ranged from 148 to 814 MBq. Specific activities ranged from 329 to 766 MBq/mg. The radiolabeling efficiency (median +/- SD) of CHX-A-DTPA-HuM195 with 213Bi was 81% +/- 9% (n = 67) after 9 min. The construct was purified by size-exclusion chromatography and was found to be 99% +/- 2% pure (n = 67) by either ITLC or HPLC methods. The immunoreactivity of (213Bi)CHX-A-DTPA-HuM195 was 89% +/- 9% (n = 44) and was independent of the specific activity. The formulated pharmaceutical was found to contain < or =4 +/- 1 EU/mL pyrogens (n = 66); all samples examined were sterile. An 225Ac radionuclidic impurity was present at a level of 0.04 +/- 0.03 x 10(-6)/mL (n = 10) in a product volume of 7.4 +/- 0.5 mL (n = 67). Each of the 67 doses was injected intravenously into patients without complication as part of a phase I clinical trial. CONCLUSION: These data show that 213Bi-labeled antibody constructs can be prepared and administered safely to humans at a wide range of therapeutic levels.  (+info)

(2/23) Tumor therapy with targeted atomic nanogenerators.

A single, high linear energy transfer alpha particle can kill a target cell. We have developed methods to target molecular-sized generators of alpha-emitting isotope cascades to the inside of cancer cells using actinium-225 coupled to internalizing monoclonal antibodies. In vitro, these constructs specifically killed leukemia, lymphoma, breast, ovarian, neuroblastoma, and prostate cancer cells at becquerel (picocurie) levels. Injection of single doses of the constructs at kilobecquerel (nanocurie) levels into mice bearing solid prostate carcinoma or disseminated human lymphoma induced tumor regression and prolonged survival, without toxicity, in a substantial fraction of animals. Nanogenerators targeting a wide variety of cancers may be possible.  (+info)

(3/23) Targeted actinium-225 in vivo generators for therapy of ovarian cancer.

Advanced ovarian cancer is largely incurable, but initially it is frequently confined to the i.p. space. We explored i.p. radioimmunotherapy in a mouse model of human ovarian cancer. Use of a targeted actinium-225 ((225)Ac) in vivo generator of alpha particles exploits the extreme, selective cytotoxicity of alpha particles, while providing a feasible half-life to enable delivery to tumor. (225)Ac chelated with 2-(p-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10 tetraacetic acid was conjugated to trastuzumab, an anti-HER-2/neu antibody. The radioimmunoconjugate was tested for immunoreactivity, internalization, and cytotoxicity using a human ovarian carcinoma cell line, SKOV3. (225)Ac-labeled trastuzumab retained immunoreactivity (50-90%), rapidly internalized into cells (50% at 2 h), and had an ED(50) of 1.3 nCi/ml after 4 days of incubation in vitro. i.p. administered (225)Ac- or (111)In-labeled trastuzumab behaved similarly with high tumor uptake [56-60% injected dose per gram (% ID/g) at 4 h, which increased to 65-70% ID/g at 24 h]. Tumor uptake was 3-5-fold higher than liver and spleen, the normal organs with the highest uptake. i.v. administration of (111)In-labeled trastuzumab produced slightly higher normal organ uptake compared with i.p.-administered (111)In-labeled trastuzumab. However, tumor uptake was low, 5%-26% ID/g. Therapy was examined with native trastuzumab and 220, 330, and 450 nCi of (225)Ac-labeled trastuzumab or (225)Ac-labeled control antibody at different dosing schedules. Therapy was initiated 9 days after tumor seeding. Groups of control mice and those administered native trastuzumab had median survivals of 33 and 37 or 44 days, respectively. Median survival was 52-126 days with (225)Ac-labeled trastuzumab at various doses and schedules, and 48-64 days for (225)Ac-labeled control the same schedules. Deaths from toxicity occurred with the highest activity levels. In conclusion, i.p. administration with a (225)Ac-labeled internalizing anti-HER-2/neu antibody can extend survival significantly in a nude mouse model of human ovarian cancer at levels that produce no apparent gross toxicity.  (+info)

(4/23) Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.

Short-lived alpha-emitting isotopes individually conjugated to monoclonal antibodies have now reached human use, but little is still known about their toxicity. Use of antibody targetable (225)Ac nanogenerators is a new approach in the field of alpha-immunotherapy offering the advantage of a 10-d half-life (t(1/2)) and increased potency due to generation of 3 new atoms, yielding a total of 4 alpha-particles. However, the 3 alpha-emitting daughter elements generated have the potential for significant toxicity as these nuclides are no longer bound to the carrier IgG. METHODS: Cynomolgus monkeys were used to evaluate the toxicity of prototype (225)Ac nanogenerators. Monoclonal antibody HuM195 (anti-CD33) is the carrier for planned human clinical trials of (225)Ac; there are no CD33 sites in cynomolgus monkeys. In one experiment, 2 monkeys received a single intravenous dose of (225)Ac-HuM195 at 28 kBq/kg. This dose level is approximately the planned initial human dose. In another experiment, 2 animals received a dose escalation schedule of 3 increasing (225)Ac-HuM195 doses with a cumulative activity of 377 kBq/kg. The whole-blood t(1/2) of (225)Ac, ratios of (225)Ac to its ultimate alpha-emitting daughter nuclide (213)Bi, generation of monkey anti-HuM195 antibodies (MAHA), hematologic indices, serum biochemistries, and clinical parameters were measured. Monkeys were euthanized and examined histopathologically when the dose escalation reached toxicity. RESULTS: The blood t(1/2) of (225)Ac-HuM195 was 12 d, and 45% of generated (213)Bi daughters were cleared from the blood. MAHA production was not detected. Approximately 28 kBq/kg of (225)Ac caused no toxicity at 6 mo, whereas a cumulative dose of approximately 377 kBq/kg caused severe toxicity. In the cumulative dosing schedule, single doses of approximately 37 kBq/kg resulted in no toxicity at 6 wk. After approximately 130 kBq/kg were administered, no toxicity was observed for 13 wk. However, 28 wk after this second dose administration, mild anemia and increases of blood urea nitrogen and creatinine were detected. After administration of an additional 185 kBq/kg, toxicity became clinically apparent. Monkeys were euthanized 13 and 19 wk after the third dose administration (cumulative dose was 377 kBq/kg). Histopathologic evaluation revealed mainly renal tubular damage associated with interstitial fibrosis. CONCLUSION: (225)Ac nanogenerators may result in renal toxicity and anemia at high doses. The longer blood t(1/2) and the lack of target cell antigens in cynomolgus monkeys may increase toxicity compared with human application. Therefore, a dose level of at least 28 kBq/kg may be a safe starting dose in humans. Hematologic and renal function will require close surveillance during clinical trials.  (+info)

(5/23) Engineered liposomes for potential alpha-particle therapy of metastatic cancer.

Disseminated, metastatic cancer is frequently incurable. Targeted alpha-particle emitters hold great promise as therapeutic agents for disseminated disease. (225)Ac is a radionuclide generator that has a 10-d half-life and results in alpha-emitting daughter elements ((221)Fr, (217)At, (213)Bi) that lead to the emission of a total of 4 alpha-particles. The aim of this study was to develop approaches for stable and controlled targeting of (225)Ac to sites of disseminated tumor metastases. Liposomes with encapsulated (225)Ac were developed to retain the potentially toxic daughters at the tumor site. METHODS: (225)Ac was passively entrapped in liposomes. To experimentally test the retention of actinium and its daughters by the liposomes, the gamma-emissions of (213)Bi were measured in liposome fractions, which were separated from the parent liposome population and the free radionuclides, at different times. Under equilibrium conditions the decay rate of (213)Bi was used to determine the concentration of (225)Ac. Measurements of the kinetics of (213)Bi activity were performed to estimate the entrapment of (213)Bi, the last alpha-emitting daughter in the decay chain. RESULTS: Stable pegylated phosphatidylcholine-cholesterol liposomes of different sizes and charge were prepared. Multiple (more than 2) (225)Ac atoms were successfully entrapped per liposome. (225)Ac retention by zwitterionic liposomes was more than 88% over 30 d. Retention by cationic liposomes was lower. A theoretical calculation showed that for satisfactory (213)Bi retention (>50%), liposomes of relatively large sizes (>650 nm in diameter) are required. (213)Bi retention was experimentally verified to be liposome-size dependent. For large liposomes, the measured (213)Bi retention was lower than theoretically predicted (less than 10%). CONCLUSION: This work supports the hypothesis that it may be possible to develop (225)Ac-based therapies by delivering multiple (225)Ac atoms in liposomes. Improvements in the retention of (225)Ac daughters will likely be necessary to fulfill this potential. Because of the size of the liposomal structures required to contain the daughters, the approach is ideally suited for locoregional therapy (e.g., intraperitoneal, intrahepatic artery, or intrathecal).  (+info)

(6/23) Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents.

The present study explores the use of alpha-particle-emitting, bone-seeking agents as candidates for targeted radiotherapy. Actinium and thorium 1,4,7,10 tetraazacyclododecane N,N',N'',N''' 1,4,7,10-tetra(methylene) phosphonic acid (DOTMP) and thorium-diethylene triamine N,N',N'' penta(methylene) phosphonic acid (DTMP) were prepared and their biodistribution evaluated in conventional Balb/C mice at four hours after injection. All three bone-seeking agents showed a high uptake in bone and a low uptake in soft tissues. Among the soft tissue organs, only kidney had a relatively high uptake. The femur/kidney ratios for 227Th-DTMP, 228-Ac-DOTMP and 227Th-DOTMP were 14.2, 7.6 and 6.0, respectively. A higher liver uptake of 228Ac-DOTMP was seen than for 227Th-DTMP and 227Th-DOTMP. This suggests that some demetallation of the 228Ac-DOTMP complex had occurred. The results indicate that 225Ac-DOTMP, 227Th-DOTMP and 227Th-DTMP have promising properties as potential therapeutic bone-seeking agents.  (+info)

(7/23) Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.

PURPOSE: The humanized monoclonal antibody, trastuzumab (Herceptin), directed against HER2/neu, has been effective in the treatment of breast cancer malignancies. However, clinical activity has depended on HER2/neu expression. Radiolabeled trastuzumab has been considered previously as a potential agent for radioimmunotherapy. The objective of this study was to investigate the efficacy of trastuzumab labeled with the alpha-particle emitting atomic generator, actinium-225 ((225)Ac), against breast cancer spheroids with different HER2/neu expression levels. (225)Ac has a 10-day half-life and a decay scheme yielding four alpha-particles. EXPERIMENTAL DESIGN: The breast carcinoma cell lines MCF7, MDA-MB-361 (MDA), and BT-474 (BT) with relative HER2/neu expression (by flow cytometry) of 1:4:18 were used. Spheroids of these cell lines were incubated with different concentrations of (225)Ac-trastuzumab, and spheroid growth was measured by light microscopy over a 50-day period. RESULTS: The activity concentration required to yield a 50% reduction in spheroid volume at day 35 was 18.1, 1.9, and 0.6 kBq/ml (490, 52, 14 nCi/ml) for MCF7, MDA, and BT spheroids, respectively. MCF7 spheroids continued growing but with a 20-30 day growth delay at 18.5 kBq/ml. MDA spheroid growth was delayed by 30-40 days at 3.7 kBq/ml; at 18.5 kBq/ml, 12 of 12 spheroids disaggregated after 70, days and cells remaining from each spheroid failed to form colonies within 2 weeks of being transferred to adherent dishes. Eight of 10 BT spheroids failed to regrow at 1.85 kBq/ml. All of the BT spheroids at activity concentrations 3.7 kBq/ml failed to regrow and to form colonies. The radiosensitivity of these three lines as spheroids was evaluated as the activity concentration required to reduce the treated to untreated spheroid volume ratio to 0.37, denoted DVR(37). An external beam radiosensitivity of 2 Gy was found for spheroids of all three of the cell lines. After alpha-particle irradiation a DVR(37) of 1.5, 3.0, and 2.0 kBq/ml was determined for MCF7, MDA, and BT, respectively. CONCLUSION: These studies suggest that (225)Ac-labeled trastuzumab may be a potent therapeutic agent against metastatic breast cancer cells exhibiting intermediate to high HER2/neu expression.  (+info)

(8/23) Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.

Labeling of specific antibodies with bifunctional chelated Actinium-225 ((225)Ac; an alpha generator) allows the formation of new, highly potent and selective alpha-emitting anticancer drugs. We synthesized and evaluated a radioimmunoconjugate based on 3F8, an IgG(3) antibody that specifically binds to ganglioside GD2, which is overexpressed by many neuroectodermal tumors including neuroblastoma. The (225)Ac-1,4,7,10-tetra-azacylododecane (DOTA)-3F8 construct was evaluated for radiochemical purity and sterility, immunoreactivity, cytotoxicity in vitro, induction of apoptosis on GD2-positive cells, as well as for pharmacological biodistribution and metabolism of the (225)Ac generator and its daughters in a nude mouse xenograft model of neuroblastoma. The (225)Ac-3F8 showed an IC(50) of 3 Bq/ml (80 pCi/ml) on the neuroblastoma cell line, NMB7, in vitro. Apoptosis of these cells was not observed. Biodistribution in mice showed specific targeting of a subcutaneous tumor; there was redistribution of the (225)Ac daughter nuclides mainly from blood to kidneys and to small intestine. Toxicity was examined in cynomolgus monkeys. Monkeys injected with 1 to 3 doses of intrathecal (225)Ac-3F8 radioimmunoconjugate (80 to 150 kBq/kg total dose) did not show signs of toxicity based on blood chemistry, complete blood counts, or by clinical evaluations. Therapeutic efficacy of intrathecal (225)Ac-3F8 was studied in a nude rat xenograft model of meningeal carcinomatosis. The (225)Ac-3F8 treatment improved survival 2-fold from 16 to 34 days (P = 0.01). In conclusion, in vivo alpha generators targeted by 3F8 warrant additional study as a possible new approach to the treatment of carcinomatous meningitis.  (+info)

*  Actinium
The isotopes of actinium range in atomic weight from 206 u (206 Ac) to 236 u (236 Ac). Actinium is found only in traces in ... Actinium gave the name to the actinide series, a group of 15 similar elements between actinium and lawrencium in the periodic ... The actinium isotope 227Ac is a transient member of the uranium-actinium series decay chain, which begins with the parent ... Actinium metal has been prepared by the reduction of actinium fluoride with lithium vapor in vacuum at a temperature between ...
*  Actinium fluoride
... (AcF3) is an inorganic compound of actinium and fluorine. Actinium fluoride can be prepared in solution or by ... Actinium fluoride is a white solid that reacts with ammonia at 900-1000 °C to yield an actinium oxyfluoride: A c F 3 + 2 N H 3 ... In the first method, actinium hydroxide is treated with hydrofluoric acid and the product precipitates: A c ( O H ) 3 + 3 H F ... Haire, Richard G. (2006). "Actinium". In Morss; Edelstein, Norman M.; Fuger, Jean. The Chemistry of the Actinide and ...
*  Cerithidium actinium
... is a species of sea snail, a marine gastropod mollusk in the family Cerithiidae. Cerithidium actinium ...
*  Isotopes of actinium
Actinium also has two meta states. Purified 227Ac comes into equilibrium with its decay products (227Th and 223Fr) after 185 ... Actinium (89Ac) has no stable isotopes and no characteristic terrestrial isotopic composition, thus a standard atomic weight ... 228Ac is extremely rare, and almost all natural actinium is 227Ac. The most stable isotopes are 227Ac with a half-life of ... Actinium series G. D. Considine, ed. (2005). "Chemical Elements". Van Nostrand's Encyclopedia of Chemistry. Wiley-Interscience ...
*  Actinium(III) oxide
... is a chemical compound containing the rare radioactive element actinium. It has the formula Ac2O3. It is ... Actinium oxide is not to be confused with Ac2O (acetic anhydride), where Ac is an abbreviation for acetyl instead of the symbol ... Actinium, Great Soviet Encyclopedia (in Russian) Sherman, Fried; Hagemann, French; Zachariasen, W. H. (1950). "The Preparation ... of the element actinium. Ac2O3 + 6HF → 2AcF3 + 3H2O Ac2O3 + 6HCl → 2AcCl3 + 3H2O 4Ac(NO3)3 → 2Ac2O3 + 12NO2 + 3O2 4Ac + 3O2 → ...
*  Actinia
... cari Actinia equina Actinia fragacea Actinia schmidti Actinia striata Actinia tenebrosa Actinia Linnaeus, 1767 World ... Actinia dubia Lesson, 1830 Actinia equina (Linnaeus, 1758) Actinia fiscella Müller, 1789 Actinia fragacea Tugwell, 1856 Actinia ... Actinia prasina Gosse, 1860 Actinia rosula Ehrenberg, 1834 Actinia rufa Müller, 1776 Actinia sali Monteiro, Sole-Cava & Thorpe ... 1833 Actinia striata Rizzi, 1907 Actinia strigata Quoy & Gaimard, 1833 Actinia tabella Drayton in Dana, 1846 Actinia tenebrosa ...
*  Actinia tenebrosa
... is similar in form to the beadlet anemone (Actinia equina) of the northern hemisphere. The column has a ... The Waratah anemone, Actinia tenebrosa is the most common species of sea anemone found in the waters of eastern Australia, and ... Fautin, Daphne (2010). "Actinia tenebrosa Farquhar, 1898". World Register of Marine Species. Retrieved 21 January 2011. H. ... Ayre, David J. (1985). "Localized Adaptation of Clones of the Sea Anemone Actinia tenebrosa". Evolution. 39 (6): 1250-1260. doi ...
*  Actinia bermudensis
... , the red, maroon or stinging anemone, is a species of sea anemone in the family Actiniidae. Actinia ... Actinia bermudensis is an omnivore. The main items of prey are gastropods, isopods and small bivalves. Other food items may ... Red Anemone (Actinia bermudensis) Marine Invertebrates of Bermuda. Retrieved 2011-12-11. Monteiro, F.A., C.M. Russo, A.M. Sole- ... Actinia bermudensis occurs in the West Indies, Bermuda and northern Florida, and there is a further, isolated population off ...
*  Passiflora actinia
ISBN 0-88192-648-5. Media related to Passiflora actinia at Wikimedia Commons Data related to Passiflora actinia at Wikispecies ... Passiflora actinia is an evergreen vine. Native to Brazil, it is a relatively cold tolerant passion flower, and can be seen in ... Passiflora actinia species of passion flower of the Passifloraceae. It flowers mainly in early spring, producing white, mauve ...
*  Actinia schmidti
... but size also can help Actinia schmidti is a bit larger (5 to 7 cm) than its close relative (3 to 5 cm). Actinia schmidti lives ... "Actinia schmidti (Monteiro, Sole-Cava & Thorpe, 1997)". World Register of Marine Species. uBIO (2014). "Actinia schmidti ( ... Actinia schmidti leads a benthic way of life and is an active carnivorous which catches its preys at night by displaying its ... Actinia schmidti is a common sea anemone found on rocky shores all along its range in the Mediterranean Sea, Portuguese shores ...
*  Trachydora actinia
... is a moth in the Cosmopterigidae family. It is found in Australia, where it has been recorded from New South ...
*  Actinia cari
"Celenterati - Actinia cari". Pagurus.it. Archived from the original on 2013-02-18. Retrieved 2012-10-31. " Actinia cari - Delle ... Actinia cari is a species of sea anemone in the family Actiniidae. It is native to the Mediterranean Sea where it is an ... Actinia cari lives in rocky areas, attaching itself to rocks and the underside of smooth stones. It is a common species and is ... Actinia cari grows to approximately 4-5 centimetres wide, and 8 centimetres high. It can fully retract its tentacles. It has a ...
*  Tethya actinia
... is a sea sponge belonging to the family Tethyidae. While it is highly toxic to fish, it is known to be preyed ...
*  Friedrich Oskar Giesel
He was aware of the discovery of actinium by André-Louis Debierne. In publications from 1899 and 1890 Debierne does not give ... In a now controversially reviewed process it was stated that emanium is identical to actinium, which was discovered by André- ... Giesel, on the other hand, can rightfully be credited with the first preparation of radiochemically pure actinium and with the ... Kirby, H. W. (1971). "The Discovery of Actinium". Isis. 62 (3): 290-308. doi:10.1086/350760. JSTOR 229943. Giesel, F. (1900). " ...
*  Cerithidium
... actinium Rehder, 1980. Retrieved through: World Register of Marine Species on 17 May 2010. Cerithidium australiense ... Cerithidium actinium Rehder, 1980 Cerithidium australiense Thiele, 1930 Cerithidium cerithinum (Philippi, 1849) Cerithidium ...
*  Ada Hitchins
This research resulted in the successful identification of a new element in the decay chain between uranium-235 and actinium, ... Soddy, F.; Cranston, J. A. (1 June 1918). "The Parent of Actinium". Proceedings of the Royal Society A: Mathematical, Physical ... on the possible modes of origin of actinium. With regard to the new work, in the absence of one of us on military service since ...
*  André-Louis Debierne
In 1899, he discovered the radioactive element actinium, as a result of continuing the work with pitchblende that the Curies ... H. W. Kirby (1971). "The Discovery of Actinium". Isis. 62 (3): 290-308. doi:10.1086/350760. JSTOR 229943. ESPCI ParisTech ... was a French chemist and is considered the discoverer of the element actinium. Debierne studied at the elite École supérieure ...
*  List of plants of Atlantic Forest vegetation of Brazil
Passiflora actinia Hook. Passiflora alata Dryand. Passiflora amethystina J.C.Mikan Passiflora deidamioides Harms Passiflora ...
*  1899 in science
Actinium is discovered by Andre-Louis Debierne. International Committee on Atomic Weights established. January 23 - The British ...
*  Strawberry anemone
Actinia fragacea is similar in form to the beadlet anemone (Actinia equina) and was at one time considered to be a variant of ... The strawberry anemone (Actinia fragacea) is an Anthozoan of the order Actiniaria, a sea anemone, that occurs from Norway to ... 113-. ISBN 978-94-011-5888-6. "Strawberry anemone - Actinia fragacea". MarLIN. Retrieved 2015-08-18. Encyclopedia of Marine ...
*  Beadlet anemone
Actinia equina is similar in form to the Waratah anemone (Actinia tenebrosa) of Australia and New Zealand. It is also similar ... The beadlet anemone, Actinia equina, is a common sea anemone found on rocky shores around all coasts of the United Kingdom and ... Actinia equina can be found both in exposed and sheltered situations. It is highly adapted to the intertidal zone as it can ... Actinia equina is viviparous, with up to one hundred embryos developing inside the body cavity before being ejected into the ...
*  Metridium farcimen
A further study in 2000 concluded that Actinia priapus; Tilesius, 1809, Actinia farcimen; Brandt, 1835, and Isometridium ... Of these, Actinia farcimen was the name first published. It is, however, a junior homonym so the valid name for the species is ...
*  Sonia Cotelle
Cotelle "collaborated with Curie on studies of actinium. With Curie she redetermined the half life of ionium using a method ...
*  89 (number)
Eighty-nine is: The atomic number of actinium. Messier object M89, a magnitude 11.5 elliptical galaxy in the constellation ...
*  Thomas Russell Wilkins
"The Actinium Series and the Lead Ratios in Rocks." Nature 117 (1926): 719-720. doi:10.1038/117719b0 with W. M. Rayton: " ...
Actinium Pharmaceuticals Further Strengthens Team Adding an Accomplished Finance and Corporate Development Professional  Actinium Pharmaceuticals Further Strengthens Team Adding an Accomplished Finance and Corporate Development Professional
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ('Actinium' or 'the Company') is a biopharmaceutical Company developing ... Actinium announced today the appointment of Steve O'Loughlin to the position of Senior Director of Finance and... ... "Actinium is pleased to welcome Steve to team," said Sandesh Seth, Executive Chairman of Actinium. "As we continue to progress ... About Actinium Pharmaceuticals Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical ...
more infohttp://www.marketwired.com/press-release/actinium-pharmaceuticals-further-strengthens-team-adding-accomplished-finance-corporate-2063179.htm
Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced...  Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced...
The purpose of this study is to find a safe dose of actinium-225 when it is labeled to HuM195. This will be done with a 'phase ... Biological: ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195 A single infusion of 225Ac-HuM195 will be ... The starting dose of actinium-225 in this study is less than doses that are known to be safe in animals. ... Biological: ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195 Phase 1 ...
more infohttps://clinicaltrials.gov/show/NCT00672165
Actinium Announces Acceptance of Actimab-A Data for Poster Presentation at American Society of Hematology Annual Meeting -...  Actinium Announces Acceptance of Actimab-A Data for Poster Presentation at American Society of Hematology Annual Meeting -...
19, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ( ... Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a ... About Actinium Pharmaceuticals Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical ... 19, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical ...
more infohttps://www.bioportfolio.com/news/article/2877287/Actinium-Announces-Acceptance-of-Actimab-A-Data-for-Poster-Presentation-at-American.html
Thorium: The mineralogy of Thorium  Thorium: The mineralogy of Thorium
Actinium ,, Thorium ,, Protactinium. Most widespread minerals containing Thorium. This list of minerals containing Thorium is ...
more infohttps://www.mindat.org/element/Thorium
Actinium Series | Encyclopedia.com  Actinium Series | Encyclopedia.com
Overview Actinium is the third element in Row 7 of the periodic table [1], a chart that shows how the chemical elements are ... ACTINIUM (REVISED) Note: This article, originally published in 1998, was updated in 2006 for the eBook edition. ... About a dozen isotopes of actinium are known. All are radioactive. The two that occur in nature are actinium-227 and actinium- ... Actinium Chemistry: Foundations and Applications COPYRIGHT 2004 The Gale Group, Inc.. Actinium. melting point: 1,050°C. boiling ...
more infohttps://www.encyclopedia.com/science-and-technology/physics/physics/actinium-series
Actinium»properties of free atoms [WebElements Periodic Table]  Actinium»properties of free atoms [WebElements Periodic Table]
This WebElements periodic table page contains properties of free atoms for the element actinium ... The ionisation energies of actinium are given below.. Ionisation energies of actinium. Ionisation energy number. Enthalpy / kJ ... A representation of the atomic spectrum of actinium.. Electronic configuration of neutral atomic actinium The electronic ... The ground state electron configuration of ground state gaseous neutral actinium is [Rn].6d1.7s2 and the term symbol is 2D3/2. ...
more infohttps://www.webelements.com/actinium/atoms.html
Actinium Announces $5 Million Registered Direct Offering of Common Stock  Actinium Announces $5 Million Registered Direct Offering of Common Stock
Actinium Pharmaceuticals, Inc. , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the ... About Actinium Pharmaceuticals. Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical ... NEW YORK, NY--(Marketwired - June 04, 2015) - Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE MKT: ATNM), a ... Actinium undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, ...
more infohttps://finance.yahoo.com/news/actinium-announces-5-million-registered-183525790.html
Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference  Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
6, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTC BB: CTVN) a biopharmaceutical company that develops innovative ... About Actinium Pharmaceuticals. Actinium Pharmaceuticals, Inc. is a New York, New York based biopharmaceutical company that ... Jack Talley, Actinium's President & CEO will be presenting at the 15th Annual BIO CEO & Investor Conference on Monday, February ... Forward-Looking Statement for Actinium Pharmaceuticals, Inc.. This news release contains 'forward-looking statements' as that ...
more infohttps://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-to-present-at-the-15th-annual-bio-ceo-investor-conference-190070791.html
Actinium - Wikipedia  Actinium - Wikipedia
The isotopes of actinium range in atomic weight from 206 u (206 Ac) to 236 u (236 Ac). Actinium is found only in traces in ... Actinium gave the name to the actinide series, a group of 15 similar elements between actinium and lawrencium in the periodic ... The actinium isotope 227Ac is a transient member of the uranium-actinium series decay chain, which begins with the parent ... Actinium metal has been prepared by the reduction of actinium fluoride with lithium vapor in vacuum at a temperature between ...
more infohttps://en.wikipedia.org/wiki/Actinium
ORNL increases production of actinium-227 to meet demand for cancer drug  ORNL increases production of actinium-227 to meet demand for cancer drug
The Department of Energy's Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a ... ORNL increases production of actinium-227 to meet demand for cancer drug. *Download PDF Copy ... The Department of Energy's Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a ...
more infohttps://www.news-medical.net/news/20180601/ORNL-increases-production-of-actinium-227-to-meet-demand-for-cancer-drug.aspx
Actinium Pharmaceuticals to Present at Biotech Showcase 2016 | Equities.com  Actinium Pharmaceuticals to Present at Biotech Showcase 2016 | Equities.com
NEW YORK, NY--(January 11, 2016) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium"), a biopharmaceutical company ... Actinium Pharmaceuticals to Present at Biotech Showcase 2016 Press Releases Follow , Monday, 11 January 2016 10:07 (EST). Live ... Actinium Pharmaceuticals, Inc. [email protected] DISCLOSURE: The views and opinions expressed in this article are ... Actinium's management will host one-on-one meetings with conference attendees at Biotech Showcase 2016, which can be scheduled ...
more infohttps://www.equities.com/news/actinium-pharmaceuticals-to-present-at-biotech-showcase-2016
Actinium Pharmaceuticals Inc. (Delaware) (ATNM) Market Data & News - Equities.com  Actinium Pharmaceuticals Inc. (Delaware) (ATNM) Market Data & News - Equities.com
Actinium Appoints Robert N. Daly, Ph.D. to Newly Created Role of Vice President, Head of Clinical Operations September 06, 2018 ... Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease ... Actinium to Provide Update on Pivotal Phase 3 SIERRA Trial Following Positive Data Monitoring Committee Meeting August 14, 2018 ... Actinium Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussions September 04 ...
more infohttps://www.equities.com/companies/atnm
Actinium fluoride - Wikipedia  Actinium fluoride - Wikipedia
Actinium fluoride (AcF3) is an inorganic compound of actinium and fluorine. Actinium fluoride can be prepared in solution or by ... Actinium fluoride is a white solid that reacts with ammonia at 900-1000 °C to yield an actinium oxyfluoride: A c F 3 + 2 N H 3 ... In the first method, actinium hydroxide is treated with hydrofluoric acid and the product precipitates: A c ( O H ) 3 + 3 H F ... Haire, Richard G. (2006). "Actinium". In Morss; Edelstein, Norman M.; Fuger, Jean. The Chemistry of the Actinide and ...
more infohttps://en.wikipedia.org/wiki/Actinium_fluoride
Research Reports Initiation on Biotech Stocks -- Agenus, Athersys, Actinium Pharma, and AVEO Pharma  Research Reports Initiation on Biotech Stocks -- Agenus, Athersys, Actinium Pharma, and AVEO Pharma
NASDAQ: ATHX), Actinium Pharmaceuticals Inc. (NYSE MKT: ATNM), and AVEO Pharmaceuticals ... Actinium Pharma Shares in New York-based Actinium Pharmaceuticals Inc. recorded a trading volume of 155,920 shares. The stock ... Research Reports Initiation on Biotech Stocks -- Agenus, Athersys, Actinium Pharma, and AVEO Pharma. Friday, May 19, 2017 Drug ... On May 17th, 2017, Actinium Pharma announced that Dr. Richard Stone, Chief of Staff and Program Director, Acute Leukemia at the ...
more infohttps://www.medindia.net/health-press-release/Research-Reports-Initiation-on-Biotech-Stocks-Agenus-Athersys-Actinium-Pharma-and-AVEO-Pharma-328039-1.htm
Actinia | Definition of Actinia by Websters Online Dictionary  Actinia | Definition of Actinia by Webster's Online Dictionary
Actinia explanation. Define Actinia by Webster's Dictionary, WordNet Lexical Database, Dictionary of Computing, Legal ... Actinia - a genus of sea anemone common in rock pools. Synonyms: genus Actinia ... Actinia Ac`tin´i`a. n.. 1.. (Zool.) An animal of the class Anthozoa, and family Actinidæ. . From a resemblance to flowers in ... Actinaria, Actiniaria, coelenterate genus, genus Actinia, order Actinaria, order Actiniaria. Translate Actinia to French ...
more infohttp://www.webster-dictionary.org/definition/Actinia
Actinium Pharmaceuticals, Inc. (ATNM) and SCYNEXIS, Inc. (SCYX) Activist Update  Actinium Pharmaceuticals, Inc. (ATNM) and SCYNEXIS, Inc. (SCYX) Activist Update
Actinium Pharmaceuticals, Inc. (ATNM) - Frigate Ventures LP has filed a new SC 13G, reporting a 5.50% ownership stake in ... Actinium Pharmaceuticals, Inc. (ATNM) and SCYNEXIS, Inc. (SCYX) Activist Update. March 13, 2018 at 9:30 pm. by Fintel ... Actinium Pharmaceuticals, Inc. has declared a standard industrial code (sic) of 2834 which is the "Pharmaceutical Preparations ... disclosing ownership of 6,000,000 shares of Actinium Pharmaceuticals, Inc. (AMEX:ATNM). This represents 5.5 percent ownership ...
more infohttps://www.valuewalk.com/2018/03/actinium-pharmaceuticals-atnm-scynexis-inc-scyx/
Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease  Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease
20, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) today announced that the Company will participate ... About Actinium Pharmaceuticals, Inc.. Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on ... Actinium is also developing its proprietary Actinium Warhead Enabling (AWE) technology platform to utilize the highly ... Actinium Pharmaceuticals, Inc. Steve O'Loughlin. Principal Financial Officer. [email protected] Investor Relations ...
more infohttps://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-participate-in-the-oppenheimer--co-fall-summit-focused-on-specialty-pharma-and-rare-disease-300715908.html
FIGHTING CANCER, CELL BY CELL Trademark of Actinium Pharmaceuticals, Inc.. Serial Number: 76196492 :: Trademarkia Trademarks  FIGHTING CANCER, CELL BY CELL Trademark of Actinium Pharmaceuticals, Inc.. Serial Number: 76196492 :: Trademarkia Trademarks
CELL BY CELL is a trademark and brand of Actinium Pharmaceuticals, Inc.. Filed to USPTO On Friday, January 19, 2001, The ... This is a brand page for the FIGHTING CANCER, CELL BY CELL trademark by Actinium Pharmaceuticals, Inc. in Alexandria, , 22314. ... On Friday, January 19, 2001, a U.S. federal trademark registration was filed for FIGHTING CANCER, CELL BY CELL by Actinium ... Actinium Pharmaceuticals, Inc.. Alexandria 22314 Why is this contact information displayed? Why is this contact information ...
more infohttps://www.trademarkia.com/fighting-cancer-cell-by-cell-76196492.html
  • Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. (yahoo.com)
  • Significant research has been done in the separation of the alpha emitter Bismuth-213 from its parent solution of Actinium-225 using organic resins. (tennessee.edu)
  • Due to radiolytic damage to the resin emphasis in the research has focused on the rapid elution of Bismuth-213 or storage of the parent Actinium-225 solution on a more robust resin. (tennessee.edu)
  • If an inorganic resin could retain its structural integrity then Actinium-225 could be loaded on an inorganic resin bed with a clinical dose of Bismuth-213 eluted from the column when needed. (tennessee.edu)
  • The performance of two inorganic ion exchange resins, Isolute SCX and Isolute SCX-2, were compared to the performance of the organic resin AG-50X8 in the separation of the radionuclide Bismuth-213 from its parent solution of Actinium-225. (tennessee.edu)
  • Performance was based on the percent of Bismuth-213 available eluted, and the breakthrough of Actinium-225. (tennessee.edu)
  • Moore, Mark Alan, "The Separation of Bismuth-213 from Actinium-225 and the Ion Exchange Properties of the Alkali Metal Cations with an Inorganic Resin. (tennessee.edu)
  • When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. (bioportfolio.com)
  • Our most advanced alpha-particle based therapy, Actimab-A, is an anti-CD33 monoclonal antibody conjugated with the alpha-particle actinium-225 (Ac-225). (businessinsider.com)
  • On May 17 th , 2017, Actinium Pharma announced that Dr. Richard Stone , Chief of Staff and Program Director, Acute Leukemia at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School , has joined the Company's Scientific Advisory Board (SAB). (medindia.net)
  • The unstable radium decays, gives off radiation, and changes to actinium. (encyclopedia.com)
  • Actinium is found only in traces in uranium and thorium ores as the isotope 227Ac, which decays with a half-life of 21.772 years, predominantly emitting beta and sometimes alpha particles, and 228Ac, which is beta active with a half-life of 6.15 hours. (wikipedia.org)
  • Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. (bioportfolio.com)
  • The name actinium originates from the Ancient Greek aktis, aktinos (ακτίς, ακτίνος), meaning beam or ray. (wikipedia.org)
  • I look forward to leveraging my experience and relationships to further enhance the profiles of Actinium s drug candidates to the hematology and bone marrow transplant community while positioning them for future success. (salesandmarketingnetwork.com)
  • We are currently conducting clinical trials for our three product candidates, Iomab-B, Actimab-A and Actimab-M, as well as performing research on other potential drug candidates utilizing our proprietary actinium-225 technology platform. (businessinsider.com)
  • We expect our Actinium-225 Technology Platform will generate additional drug candidates that we will progress in clinical trials ourselves and or out-license. (businessinsider.com)
  • A soft, silvery-white radioactive metal, actinium reacts rapidly with oxygen and moisture in air forming a white coating of actinium oxide that prevents further oxidation. (wikipedia.org)
  • With Iomab-B poised to enter a pivotal Phase 3 trial, Actimab-A moving towards a Phase 2 trial and an ever strengthening team it is an honor to join Actinium at such a momentous time for the Company. (marketwired.com)
  • Actinium is the third element in Row 7 of the periodic table , a chart that shows how the chemical elements are related to each other. (encyclopedia.com)
  • Actinium gave the name to the actinide series, a group of 15 similar elements between actinium and lawrencium in the periodic table. (wikipedia.org)
  • Actinium is also developing its proprietary Actinium Warhead Enabling (AWE) technology platform to utilize the highly differentiated radioisotope actinium-225 with a wide range of targets. (prnewswire.com)
  • A representation of the atomic spectrum of actinium. (webelements.com)
  • Actinium is a chemical element with symbol Ac and atomic number 89. (wikipedia.org)
  • Giesel, on the other hand, can rightfully be credited with the first preparation of radiochemically pure actinium and with the identification of its atomic number 89. (wikipedia.org)
  • SAB is comprised of independent physicians considered to be key opinion leaders in the field of hematology and bone marrow transplant that contribute to and advise Actinium on the development of Iomab-B, the Company's lead asset. (medindia.net)
  • The Department of Energy's Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer. (news-medical.net)
  • Or, contact the owner Actinium Pharmaceuticals, Inc. of the FIGHTING CANCER, CELL BY CELL trademark by filing a request to communicate with the Legal Correspondent for licensing, use, and/or questions related to the FIGHTING CANCER, CELL BY CELL trademark. (trademarkia.com)
  • I am very excited to join the Actinium team and eager to assume my responsibilities," said Mr. O'Loughlin. (marketwired.com)
  • Actinium is developing a pipeline of clinical-stage ARCs targeting CD45 and CD33 for patients with a broad range of hematologic malignancies. (prnewswire.com)
  • Actinium had previously reported a 56% response rate in patients that were evaluable at time of the abstract submission when data were available on 9 patients compared to the 13 patients reported in the poster. (globenewswire.com)
  • Actinium metal of 98 percent purity - used for research purposes - can be made by this process. (encyclopedia.com)
  • In the first method, actinium hydroxide is treated with hydrofluoric acid and the product precipitates: A c ( O H ) 3 + 3 H F ⟶ A c F 3 ↓ + 3 H 2 O {\displaystyle \mathrm {Ac(OH)_{3}+\ 3\ HF\longrightarrow AcF_{3}\downarrow +\ 3\ H_{2}O} } In the solid-state reaction, actinium metal is treated with hydrogen fluoride gas at 700 °C in a platinum crucible. (wikipedia.org)
  • Chief Medical Officer, Actinium Pharmaceuticals, Inc. (wsj.com)
  • Dr. Mark S. Berger, MD, is Chief Medical Officer at Actinium Pharmaceuticals, Inc. Dr. Berger was previously employed as Vice President-Clinical Development by Gemin X Pharmaceuticals US, Inc., Group Director-Clinical Oncology by GlaxoSmithKline Plc, a Principal by University of Pennsylvania, and Senior Director-Oncology Clinical Development by Wyeth Pharmaceuticals, Inc. He received his undergraduate degree from Wesleyan University and a doctorate degree from the University of Virginia. (wsj.com)
  • In this role, Steve will initially focus on pre-commercial efforts including strategic planning and product messaging for Iomab-B, increasing awareness for Iomab-B, further developing relationships with the physician community, and supporting clinical trials for Actinium s current and future clinical programs. (salesandmarketingnetwork.com)
  • Owing to its scarcity, high price and radioactivity, actinium has no significant industrial use. (wikipedia.org)
  • Actinium continues to progress Iomab-B and Actimab-A through the clinic in indications with significant unmet medical needs while expanding its pipeline and I look forward to communicating and interacting with the investment community on our developments. (marketwired.com)
  • Steve brings to Actinium a significant amount of knowledge and experience specific to hematology and also has deep relationships that he curated in his 30 years in this field. (salesandmarketingnetwork.com)